Cargando…

Practical Synthesis of 5,7-Dichlorotetrahydroisoquinoline-6-carboxylic Acid—Key Intermediate of Lifitegrast (Xiidra)

[Image: see text] In the present study, a practical method for synthesizing the key intermediate 5,7-dichlorotetrahydroisoquinoline-6-carboxylic acid (1) of Lifitegrast was proposed. First, an investigation was conducted into the utilization of the impurity and recrystallization method in the synthe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Xu, Guo, Heng, Peng, Peng, Li, Yaping, Yang, Jiangtao, Wu, Chuanjun, Xu, Shengjun, Zhao, Chuanmeng, Zhang, Fuli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2023
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233828/ https://www.ncbi.nlm.nih.gov/pubmed/37273640 http://dx.doi.org/10.1021/acsomega.3c02188

Ejemplares similares

Real-World Experience with Lifitegrast Ophthalmic Solution (Xiidra(®)) in the US and Canada: Retrospective Study of Patient Characteristics, Treatment Patterns, and Clinical Effectiveness in 600 Patients with Dry Eye Disease
por: Hovanesian, John A, et al.
Publicado: (2021)

Dry eye syndrome: developments and lifitegrast in perspective
por: Lollett, Ivonne V, et al.
Publicado: (2018)

Lifitegrast: A novel drug for treatment of dry eye disease
por: Abidi, Afroz, et al.
Publicado: (2016)

Lifitegrast: a novel drug for patients with dry eye disease
por: Haber, Stacy L., et al.
Publicado: (2019)

Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort
por: Gonzalez, Agustin L
Publicado: (2018)

Ocular Distribution and Pharmacokinetics of Lifitegrast in Pigmented Rabbits and Mass Balance in Beagle Dogs
por: Chung, Jou-Ku, et al.
Publicado: (2018)

Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease
por: Semba, Charles P, et al.
Publicado: (2016)

The Effect of Lifitegrast on Refractive Accuracy and Symptoms in Dry Eye Patients Undergoing Cataract Surgery
por: Hovanesian, John, et al.
Publicado: (2020)

Design, synthesis, and LFA-1/ICAM-1 antagonist activity evaluation of Lifitegrast analogues
por: Du, Guoxin, et al.
Publicado: (2022)

Longitudinal changes in dry eye symptoms and signs following lifitegrast therapy and relationship to tear osmolarity
por: Pepose, Jay S, et al.
Publicado: (2019)

Lifitegrast add-on treatment for dupilumab-induced ocular surface disease (DIOSD): A novel case report
por: Zirwas, Matthew J., et al.
Publicado: (2018)

Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy
por: Godin, Morgan R, et al.
Publicado: (2017)

LIFITEGRAST 5% FOR DRY EYE DISEASE: COMBINED EFFICACY AND SAFETY FROM FIVE RANDOMIZED CONTROLLED TRIALS
por: Gonzalez, Agustin L, et al.
Publicado: (2019)

Six months' treatment with lifitegrast in patients with moderate-to-severe symptomatic dry eye: a retrospective chart review
por: Atallah, Richard Teofilo, et al.
Publicado: (2019)

Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
por: White, Darrell E, et al.
Publicado: (2019)

Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial
por: Nichols, Kelly K, et al.
Publicado: (2018)

Safety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye disease
por: Nichols, Kelly K, et al.
Publicado: (2018)

A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease
por: McMullin, David, et al.
Publicado: (2021)

Lifitegrast Ophthalmic Solution 5% Is a Safe and Efficient Eyedrop for Dry Eye Disease: A Systematic Review and Meta-Analysis
por: Li, Jing-Xing, et al.
Publicado: (2022)

Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial [Corrigendum]
Publicado: (2018)

Reduction of Artificial Tears and Use of Adjunctive Dry Eye Therapies After Lifitegrast Treatment: Evidence from Clinical and Real-World Studies
por: Nichols, Kelly K, et al.
Publicado: (2022)

Production of Putative Diterpene Carboxylic Acid Intermediates of Triptolide in Yeast
por: Forman, Victor, et al.
Publicado: (2017)

Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study
por: Donnenfeld, Eric D., et al.
Publicado: (2016)

Vacant Seat on the 7.57
por: Payne, John
Publicado: (1970)

Is isoprenylcysteine carboxyl methyltransferase the key to reverse ageing?
por: Grams, Danielle, et al.
Publicado: (2013)

Identification of Key Residues for Enzymatic Carboxylate Reduction
por: Stolterfoht, Holly, et al.
Publicado: (2018)

5,7-Dimethoxyisobenzofuran-1(3H)-one
por: Sun, Ming-Xue, et al.
Publicado: (2009)

Efficacy of Lifitegrast Ophthalmic Solution, 5.0%, in Patients With Moderate to Severe Dry Eye Disease: A Post Hoc Analysis of 2 Randomized Clinical Trials
por: Holland, Edward J., et al.
Publicado: (2021)

Effects of 5,7-dihydroxytriptamine (5,7-DHT) on circadian locomotor activity of the blow fly, Calliphora vicina
por: Cymborowski, Bronislaw
Publicado: (2003)

MySQL 5.7 : administración y optimización /
por: Combaudon, Stéphane
Publicado: (2018)

Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis
por: Karpecki, Paul, et al.
Publicado: (2023)

Glutamine 57 at the Complementary Binding Site Face Is a Key Determinant of Morantel Selectivity for α7 Nicotinic Receptors
por: Bartos, Mariana, et al.
Publicado: (2009)

PYTHIA 5.7 and JETSET 7.4: Physics and manual
por: Sjostrand, Torbjorn
Publicado: (1993)

Penicillin acylase-catalyzed synthesis of N-bromoacetyl-7-aminocephalosporanic acid, the key intermediate for the production of cefathiamidine
por: Zhang, Xiao-Li, et al.
Publicado: (2016)

Key sub-community dynamics of medium-chain carboxylate production
por: Lambrecht, Johannes, et al.
Publicado: (2019)

Cutting edge: pre-intermediate : workbook : with key
por: Moor, Peter, et al.
Publicado: (2003)

Synthesis of the Key Intermediate of Coenzyme Q(10)
por: Mu, Fan-Song, et al.
Publicado: (2011)

5,7-Dichloroquinolin-8-ol
por: Ng, Seik Weng
Publicado: (2009)

Limited Overlap Between Intermediate Hyperglycemia as Defined by A1C 5.7–6.4%, Impaired Fasting Glucose, and Impaired Glucose Tolerance
por: Saukkonen, Tuula, et al.
Publicado: (2011)

Poly[(μ(4)-1,2,3-benzothiadiazole-7-carboxylato)silver(I)]
por: Zhao, Jiong-Peng, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_aco4680dmsodhnjugsngtvg231